Rankings · Price against the business
Most free cash flow per dollar of price
Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.
152 companies meet this test
Figures as of October 1, 2026
| # | Company | Grade | Free cash flow yield | P/E | Revenue growth | Market value |
|---|---|---|---|---|---|---|
| 1 | AMNAMN HEALTHCARE SERVICES, INC. | B | 32.5% | 12.99 | -8% a year | $1.4B |
| 2 | ARDTArdent Health, Inc. | A | 20.4% | 19.29 | +8% a year | $1.5B |
| 3 | NUTXNUTEX HEALTH INC. | B+ | 19.1% | 8.31 | — | $1.4B |
| 4 | TAKTakeda Pharmaceutical Company Limited | B | 18.6% | 43.25 | +4% a year | $29.7B |
| 5 | GRFSGrifols SA | A | 17.9% | 27.95 | +7% a year | $5B |
| 6 | GDRXGoodRx Holdings, Inc. | B | 17.7% | 80.75 | +2% a year | $1.1B |
| 7 | BCRXBIOCRYST PHARMACEUTICALS, INC. | A | 17.7% | — | +45% a year | $2.1B |
| 8 | PCRXPACIRA BIOSCIENCES, INC. | A | 17.5% | 73.34 | +4% a year | $1B |
| 9 | SNYSanofi | B | 16.5% | 8.91 | +2% a year | $49.7B |
| 10 | HRMYHARMONY BIOSCIENCES HOLDINGS, INC. | A+ | 15.2% | 12.71 | +24% a year | $2.3B |
| 11 | THCTENET HEALTHCARE CORP | A+ | 14.6% | 9.94 | +3% a year | $20.8B |
| 12 | DVADAVITA INC. | A | 14.4% | 14.41 | +6% a year | $11.2B |
| 13 | AMPHAmphastar Pharmaceuticals, Inc. | A+ | 13.5% | 15.80 | +11% a year | $1.1B |
| 14 | INVAINNOVIVA, INC. | B+ | 12.4% | 5.14 | +15% a year | $1.5B |
| 15 | ANIPANI PHARMACEUTICALS, INC | A+ | 10.9% | 15.67 | +35% a year | $1.6B |
| 16 | CNMDCONMED CORPORATION | B | 10.8% | 30.93 | +10% a year | $1.4B |
| 17 | JAZZJazz Pharmaceuticals plc | A+ | 10.5% | 15.89 | +7% a year | $15.1B |
| 18 | HCSGHEALTHCARE SERVICES GROUP, INC. | A+ | 10.4% | 12.22 | +4% a year | $1.4B |
| 19 | SGRYSurgery Partners, Inc. | B- | 9.9% | — | +8% a year | $1.9B |
| 20 | OMCLOMNICELL, INC | A | 9.1% | 40.79 | 0% a year | $1.6B |
| 21 | BMYBRISTOL-MYERS SQUIBB COMPANY | B+ | 8.9% | 13.85 | +3% a year | $128.4B |
| 22 | ZBHZIMMER BIOMET HOLDINGS, INC. | A | 8.7% | 22.17 | +6% a year | $17.4B |
| 23 | CAHCardinal Health, Inc. | A | 8.7% | 30.98 | +7% a year | $52.1B |
| 24 | HCAHCA Healthcare, Inc. | A | 8.3% | 14.86 | +8% a year | $95.7B |
| 25 | EXELExelixis Inc | A+ | 8.1% | 18.45 | +12% a year | $14.5B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.